Is a
Patent attributes
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
Date of Patent
December 27, 2022
Patent Application Number
16521470
Date Filed
July 24, 2019
Patent Primary Examiner
The invention relates to an anti-CD16A antigen binding protein for use in NK cell-based immunotherapy, wherein the anti-CD16A antigen binding protein is to be administered intermittently and in combination with a cytokine. In certain embodiments the antigen binding protein is a tetravalent and bispecific CD30/CD16A tandem diabody.
Timeline
No Timeline data yet.
Further Resources
No Further Resources data yet.
